All that glitters: Sorafenib

Internal Medicine

Volumn 50, Issue 7, 2011, Pages 797-

  Abbass, Khurram ^a,b   Dewani, Shabana ^a,b   Markert, Ronald ^b   Kaplon, Michael K ^a,b   Baumann, Michael A ^a,b  

^a Dayton Veteran's Affairs Medical Center   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Sorafenib; Tumor lysis syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CALCIUM; CREATINE; LACTATE DEHYDROGENASE; PHOSPHORUS; POTASSIUM; SORAFENIB; URIC ACID;

ADULT; ADVANCED CANCER; ALCOHOLISM; CASE REPORT; CONFUSION; DISEASE CLASSIFICATION; ECHOGRAPHY; HEPATITIS B; HUMAN; LABORATORY TEST; LETTER; LIVER CELL CARCINOMA; MALE; SOMNOLENCE; STOMACH PAIN; TREATMENT REFUSAL; TUMOR LYSIS SYNDROME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FATAL OUTCOME; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; TUMOR LYSIS SYNDROME;

EID: 79953735301     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4858     Document Type: Letter

References (3)

1. Joshita S, Yoshizawa K, Sano K, et al. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med 49: 991-994, 2010.
2. Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol 15: 4464-4466, 2009.
3. Shiozawa K, Watanabe M, Takenaka H, et al. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepatogastroenterology 57: 688-690, 2010.